Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EYPT Stock: The Clinical Trial News That Has EyePoint Pharma Investors Seeing Green Today
11:37am, Monday, 15'th Nov 2021
EyePoint Pharmaceuticals (EYPT) stock is heading higher on Monday thanks to interim results from a Phase 1 clinical trial. The post EYPT Stock: The Clinical Trial News That Has EyePoint Pharma Investo
Eyepoint Pharmaceuticals (EYPT) Stock: Why The Price Surged Today
07:25am, Monday, 15'th Nov 2021
The stock price of Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) increased by over 35% pre-market today. This is why it happened.
WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2021 Results - Earnings Call Transcript
12:27pm, Wednesday, 03'rd Nov 2021
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2021 Results - Earnings Call Transcript
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates
09:58am, Wednesday, 03'rd Nov 2021
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -23.40% and -5.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the
EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021
07:00am, Wednesday, 27'th Oct 2021
WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live
– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD –
EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
07:00am, Friday, 17'th Sep 2021
WATERTOWN, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the liv
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2021 Results - Earnings Call Transcript
02:48pm, Wednesday, 04'th Aug 2021
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2021 Results - Earnings Call Transcript
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
09:55am, Wednesday, 04'th Aug 2021
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 22.22% and 2.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board
07:00am, Monday, 02'nd Aug 2021
Chaired by Dr. Carl Regillo, illustrious leader in retinal surgery Chaired by Dr. Carl Regillo, illustrious leader in retinal surgery
EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021
08:00am, Wednesday, 28'th Jul 2021
WATERTOWN, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®
07:00am, Tuesday, 20'th Jul 2021
WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index
07:00am, Monday, 28'th Jun 2021
WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
